We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 55

Methods of medical treatment claims issues in Canada, US and Europe

  • Gowling Lafleur Henderson LLP
  • -
  • Canada, European Union, USA
  • -
  • November 30 2012

In this presentation, Scott Foster and Konrad Sechley address methods of medical treatment claims issues in Canada, US and Europe

Pharmaceutical trade marks case law round up for 2012early 2013

  • Corrs Chambers Westgarth
  • -
  • Australia, European Union, USA
  • -
  • June 6 2013

A brief wrap-up of recent decisions relating to trade marks in the pharma space from the EU, the United States and Australia

FDA and European Medicines Agency to do parallel evaluation of new drug marketing applications

  • Hodgson Russ LLP
  • -
  • European Union, USA
  • -
  • April 4 2011

FDA is always criticized and questioned about taking longer to approve regulated products than its counterpart agency in Europe, European Medicines Agency (EMA

Measure - Summer 2013

  • King & Spalding LLP
  • -
  • European Union, Middle East, Saudi Arabia, United Arab Emirates, USA
  • -
  • July 3 2013

This issue is rich in news on emerging market trends and legal developments. A revival in real estate investments has been witnessed across the globe

The patentability of stem cells: WARF's success and failure on opposite sides of the Atlantic

  • Shepherd & Wedderburn LLP
  • -
  • European Union, United Kingdom, USA
  • -
  • March 31 2008

The Wisconsin Alumni Research Foundation (WARF) has had three of its patents in relation to stem cells (and in particular, methods of isolation) upheld by the United States Patent and Trademark Office (USPTO

Transatlantic developments in relation to the antitrust analysis of reverse payment settlements: Lundbeck and Actavis

  • NautaDutilh
  • -
  • European Union, USA
  • -
  • June 21 2013

Lundbeck held various patents relating to citalopram, both in respect of the substance itself and in respect of various production processes. When the

Global corporate insurance & regulatory bulletin

  • Mayer Brown JSM
  • -
  • China, European Union, United Kingdom, USA
  • -
  • December 5 2013

The China Insurance Regulatory Commission (“CIRC”) announced new rules (Implementing Rules of Provisional Measures on Outbound Investments with

Patent claims for ‘personalised medicines’

  • Mewburn Ellis LLP
  • -
  • European Union, USA
  • -
  • February 7 2013

As previously reported the US Supreme Court, in Mayo v. Prometheus, recently invalidated Prometheus's diagnostic claims - directed to a method of

Definitions of generic competition in contracts

  • Fasken Martineau DuMoulin LLP
  • -
  • European Union, USA
  • -
  • April 6 2009

In licensing and other collaborations the onset of 'generic competition' may be cause for renegotiation of certain aspects of the agreement or reductions in payments

EU, US regulators ease process for orphan drugs

  • Gowling Lafleur Henderson LLP
  • -
  • European Union, USA
  • -
  • December 6 2007

In an effort to encourage development of drug treatments for rare diseases, the European Commission, the European Medicines Agency and the U.S. Food and Drug Administration announced steps to streamline the application process for orphan drugs